Authors:
Vamvakopoulos, JE
Taylor, CJ
Green, C
McNeil, K
Metcalfe, SM
Citation: Je. Vamvakopoulos et al., Genetic modulators of interleukin 1 activity influence the development of chronic rejection in human thoracic allografts, TRANSPLAN P, 33(1-2), 2001, pp. 1563-1564
Citation: Sd. Moffatt et Sm. Metcalfe, Comparison between tacrolimus and cyclosporine as immunosuppressive agentscompatible with tolerance induction by CD4/CD8 blockade, TRANSPLANT, 69(8), 2000, pp. 1724-1726
Citation: Sd. Moffatt et Sm. Metcalfe, FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies, TRANSPLAN P, 31(7), 1999, pp. 2740-2740
Authors:
Moffatt, SD
McAlister, V
Calne, RY
Metcalfe, SM
Citation: Sd. Moffatt et al., Comparative efficacy of liposomal FK 506 with FK 506 (tacrolimus) with andwithout anti-CD4/CD8 monoclonal antibodies, TRANSPLAN P, 31(7), 1999, pp. 2754-2754
Authors:
Hughes, JR
Hughes, VF
Trull, AK
Metcalfe, SM
Citation: Jr. Hughes et al., Blood levels of TGF beta(1) in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine, TRANSPLANT, 68(4), 1999, pp. 583-586
Authors:
Moffatt, SD
McAlister, V
Calne, RY
Metcalfe, SM
Citation: Sd. Moffatt et al., Potential for improved therapeutic index of FK506 in liposomal formulationdemonstrated in a mouse cardiac allograft model, TRANSPLANT, 67(9), 1999, pp. 1205-1208
Citation: Sm. Metcalfe et al., In vitro transcription and translation of the tumour suppressor protein p53: Qualitative and quantitative effects of FK506 and rapamycin, TRANSPLAN P, 30(8), 1998, pp. 4108-4109